Incannex Healthcare Limited American Depositary Shares

Incannex Healthcare received A$6.0 million in R&D tax incentive refunds from the Australian Government with an additional A$5.1 million expected later in 2026, totaling over A$11.1 million in non-dilutive capital. The company plans to use these proceeds to advance clinical programs including IHL-42X and PSX-001, while maintaining its share repurc...

Incannex Healthcare Inc. (Nasdaq: IXHL) has been recognized as the winner of the 'Best New Technology Solution for Drug Development' at the 10th annual MedTech Breakthrough Awards for its lead drug candidate IHL-42X, an oral fixed-dose combination therapy for obstructive sleep apnea. The Phase 2 RePOSA trial demonstrated statistically significant...

Incannex Healthcare announced an enhanced clinical development strategy for IHL-42X, its lead oral drug candidate for obstructive sleep apnea (OSA), following statistically significant Phase 2 results. The company received FDA Fast Track Designation and plans to conduct a Phase 2 crossover dose-optimization study (DReAMzz) to optimize the drug's ...

Incannex Healthcare Inc. (Nasdaq: IXHL) announced the appointment of three distinguished members to its Clinical Advisory Board: Murray B. Stein, MD, MPH from UCSD; Andrew Cutler, MD from SUNY Upstate Medical University; and Amir Kalali, MD. The CAB will provide clinical and scientific guidance as PSX-001, an oral synthetic psilocybin treatment f...

Several biotechnology firms have psychedelic treatments in development, with promising results from clinical trials. The psychedelic market is expected to grow significantly, and most investors are favorable towards psychedelic stocks.